Krystal Total Assets from 2010 to 2025

KRYS Stock

USD 187.15 0.00 0.00%

Krystal Biotech Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2016-12-31

Previous Quarter

982.3 M

Current Value

1.1 B

Quarterly Volatility

320.4 M

Covid

Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 31.1 M, Interest Income of 31.1 M or Depreciation And Amortization of 7 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 4.5. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.

Check out the analysis of Krystal Biotech Correlation against competitors.

For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Latest Krystal Biotech's Total Assets Growth Pattern

Below is the plot of the Total Assets of Krystal Biotech over the last few years. Total assets refers to the total amount of Krystal Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Krystal Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Krystal Biotech's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.06 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Krystal Total Assets Regression Statistics

	Arithmetic Mean	304,308,681
	Geometric Mean	39,099,053
	Coefficient Of Variation	131.24
	Mean Deviation	331,569,977
	Median	116,116,000
	Standard Deviation	399,362,222
	Sample Variance	159490.2T
	Range	1.1B
	R-Value	0.89
	Mean Square Error	34932.3T
	R-Squared	0.80
	Slope	74,819,393
	Total Sum of Squares	2392352.8T

Krystal Total Assets History

	2025	1.1 B
	2024	1.1 B
	2023	818.4 M
	2022	558.5 M
	2021	626.3 M
	2020	310.8 M
	2019	209 M

Other Fundumenentals of Krystal Biotech

Intangibles To Total Assets

Krystal Biotech Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Property Plant Equipment	Net Invested Capital	Net Working Capital	Common Stock	Current Deferred Revenue	Long Term Investments
Total Assets		1.0	0.96	-0.91	-0.86	0.72	-0.72	0.97	0.94	1.0	0.97	0.93	0.93	-0.72	-0.2	0.91
Total Stockholder Equity	1.0		0.97	-0.92	-0.87	0.73	-0.7	0.98	0.93	1.0	0.97	0.93	0.94	-0.73	-0.19	0.9
Net Tangible Assets	0.96	0.97		-0.94	-0.91	0.85	-0.56	1.0	0.84	0.96	0.95	0.93	0.94	-0.82	-0.02	0.78
Net Debt	-0.91	-0.92	-0.94		0.79	-0.77	0.5	-0.93	-0.76	-0.93	-0.83	-0.9	-0.93	0.86	-0.06	-0.75
Retained Earnings	-0.86	-0.87	-0.91	0.79		-0.67	0.37	-0.92	-0.69	-0.85	-0.93	-0.89	-0.89	0.73	0.26	-0.59
Accounts Payable	0.72	0.73	0.85	-0.77	-0.67		-0.29	0.82	0.6	0.72	0.72	0.78	0.77	-0.67	0.43	0.59
Long Term Debt Total	-0.72	-0.7	-0.56	0.5	0.37	-0.29		-0.59	-0.89	-0.71	-0.65	-0.45	-0.45	0.29	0.35	-0.88
Capital Surpluse	0.97	0.98	1.0	-0.93	-0.92	0.82	-0.59		0.86	0.97	0.97	0.94	0.94	-0.8	-0.09	0.8
Total Liab	0.94	0.93	0.84	-0.76	-0.69	0.6	-0.89	0.86		0.93	0.89	0.8	0.8	-0.53	-0.31	0.97
Total Current Assets	1.0	1.0	0.96	-0.93	-0.85	0.72	-0.71	0.97	0.93		0.96	0.93	0.93	-0.75	-0.19	0.9
Property Plant Equipment	0.97	0.97	0.95	-0.83	-0.93	0.72	-0.65	0.97	0.89	0.96		0.92	0.91	-0.67	-0.25	0.84
Net Invested Capital	0.93	0.93	0.93	-0.9	-0.89	0.78	-0.45	0.94	0.8	0.93	0.92		1.0	-0.72	-0.12	0.77
Net Working Capital	0.93	0.94	0.94	-0.93	-0.89	0.77	-0.45	0.94	0.8	0.93	0.91	1.0		-0.76	-0.11	0.77
Common Stock	-0.72	-0.73	-0.82	0.86	0.73	-0.67	0.29	-0.8	-0.53	-0.75	-0.67	-0.72	-0.76		-0.04	-0.45
Current Deferred Revenue	-0.2	-0.19	-0.02	-0.06	0.26	0.43	0.35	-0.09	-0.31	-0.19	-0.25	-0.12	-0.11	-0.04		-0.19
Long Term Investments	0.91	0.9	0.78	-0.75	-0.59	0.59	-0.88	0.8	0.97	0.9	0.84	0.77	0.77	-0.45	-0.19

Click cells to compare fundamentals

About Krystal Biotech Financial Statements

Krystal Biotech shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	1.1 B	1.1 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC